AUTHOR=Biswas Saumik , Coyle Ali , Chen Shali , Gostimir Miso , Gonder John , Chakrabarti Subrata 

TITLE=Expressions of Serum lncRNAs in Diabetic Retinopathy – A Potential Diagnostic Tool

JOURNAL=Frontiers in Endocrinology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.851967

DOI=10.3389/fendo.2022.851967

ISSN=1664-2392

ABSTRACT=<p>With increasing incidence of diabetes worldwide, there is an ever-expanding number of patients with chronic diabetic complications such as diabetic retinopathy (DR), one of the leading causes of blindness in the working age population. Early screening for the onset and severity of DR is essential for timely intervention. With recent advancements in genomic technologies, epigenetic alterations in DR are beginning to unravel. Long non-coding RNAs (lncRNAs), which are key epigenetic mediators, have demonstrated implications in several (DR) related processes. Based on the previous research, we have developed a serum-based, multi-panel PCR test using 9 lncRNAs (<italic>ANRIL</italic>, <italic>MALAT1</italic>, <italic>WISPER</italic>, <italic>ZFAS1</italic>, <italic>H19</italic>, <italic>HOTAIR</italic>, <italic>HULC</italic>, <italic>MEG3</italic>, and <italic>MIAT</italic>) to identify and validate whether this panel could be used as a diagnostic and prognostic tool for DR. We initially used a cell culture model (human retinal endothelial cells) and confirmed that 25 mM glucose induces upregulations of <italic>ANRIL</italic>, <italic>HOTAIR</italic>, <italic>HULC</italic>, <italic>MALAT1</italic>, and <italic>ZFAS1</italic>, and downregulation of <italic>H19</italic> compared to 5 mM glucose controls. Then as an initial proof-of-concept, we tested vitreous humor and serum samples from a small cohort of non-diabetic (N=10) and diabetic patients with proliferative retinopathy (PDR, N=11) and measured the levels of the 9 lncRNAs. Differential expressions of lncRNAs were found in the vitreous and serum of patients and showed significant correlations. We expanded our approach and assessed the same lncRNAs using samples from a larger cohort of diabetic (n= 59; M/F:44/15) and non-diabetic patients (n= 11; M/F:4/7). Significant increased lncRNA expressions of <italic>ANRIL</italic>, <italic>H19</italic>, <italic>HOTAIR</italic>, <italic>HULC</italic>, <italic>MIAT</italic>, <italic>WISPER</italic> and <italic>ZFAS1</italic> were observed in the serum of diabetic patients (with varying stages of DR) compared to non-diabetics. No significant correlations were demonstrated between lncRNA expressions and creatinine or glycated hemoglobin (HbA1C) levels. Using ROC and further analyses, we identified distinct lncRNA phenotype combinations, which may be used to identify patients with DR. Data from this study indicate that a panel of serum lncRNAs may be used for a potential screening test for DR. Further large-scale studies are needed to validate this notion.</p>